I'm LongbridgeAI, I can summarize articles.SUIC Worldwide Holdings acquired a 51% stake in Vision Renu via a share exchange agreement, issuing 30 million shares representing approximately 35% of its fully diluted outstanding stock. The transaction aims to expand SUIC's presence in the medtech sector and accelerate growth through FDA-path assets. Following the deal, SUIC reconstituted its board, appointing Chen King Te as Chairman and CEO and Shan Hua Peng as CFO.
SUIC Worldwide Holdings entered into a Share Exchange Agreement to acquire 51% of Vision Renu in exchange for 30,000,000 shares of SUIC common stock. The Exchange Shares are expected to represent about 35% of SUIC’s fully diluted outstanding shares, and the parties intend the deal to qualify as a tax-free reorganization under Section 368(a). Following the effective time, SUIC reconstituted its board and appointed Chen King Te as Chairman and CEO and Shan Hua Peng as CFO.
Agreement details:
- Agreement type: Share Exchange Agreement for 51% acquisition
- Counterparty: Vision Renu
- Signed / Effective: Jul 10 2026 / same
- Duration / Termination: N/A
- Reason: Expand into medtech and accelerate growth with FDA-path assets
Original SEC Filing: SUIC Worldwide Holdings Ltd. [ SUIC ] - 8-K - Jul. 10, 2026